In vivo LNA™ microRNA Inhibitors

Features

Exiqon uses empirically developed tools to design optimal LNA™ microRNA in vivo inhibitors.

Coverage

The in vivo microRNA inhibitors are provided with complete phosphorothioate backbones and are delivered dried down as Na+ salt ready to be dissolved in PBS. The inhibitors can be provided pre-labeled with fluorescein or conjugated to cholesterol. Synthesis scales ranging from 10-100 mg are available.

Effective microRNA inhibitors with low toxicity

LNA™ oligonucleotides have higher affinities for their targets than regular DNA or RNA based oligonucleotides. This means that short but highly sequence specific oligonucleotides can be used for in vivo knockdown experiments.

The high affinity of the LNA™-enhanced microRNA inhibitors makes them highly effective at physiological temperatures and when used in low concentrations, thereby minimizing potential secondary effects not related to the antisense activity of the microRNA inhibitor. In addition, LNA™ incorporation enhances serum and nuclease stability.

The LNA™ technology has been successfully applied in vivo, combining low concentrations of the microRNA inhibitor with high serum stability and low toxicity. Effective inhibition of microRNAs has been observed with concentrations of in vivo LNA™ microRNA Inhibitors as low as 10 mg/kg (ED50) bodyweight.

To learn more, please see the scientific publications listed in the right-hand menu.